The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases

被引：6

作者：

Brooks, P. J. ^{[1
]}

Miller, Timothy M. ^{[2
]}

Revah, Frederic ^{[3
]}

Suh, Junghae ^{[4
]}

Garrison, Bradley R. ^{[5
]}

Starke, Lawrence C. ^{[6
]}

MacLachlan, Timothy K. ^{[7
]}

Neilan, Edward G. ^{[8
]}

Raychaudhuri, Gopa ^{[9
]}

Kassim, Sadik H. ^{[10
]}

Dehdashti, Jean ^{[1
]}

Rutter, Joni L. ^{[1
]}

机构：

[1] NIH, Natl Ctr Adv Translat Sci, Bethesda, MD 20892 USA

[2] Thermo Fisher Sci, Waltham, MA USA

[3] Genethon, Evry, France

[4] Biogen Inc, Cambridge, MA USA

[5] Fdn Natl Inst Hlth, North Bethesda, MD USA

[6] Novartis Pharmaceut, E Hanover, NJ USA

[7] Novartis, Biomed Res, Cambridge, MA USA

[8] Natl Org Rare Disorders, Quincy, MA USA

[9] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA

[10] Danaher Corp, Washington, DC USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2024年 / 23卷 / 03期

关键词：

D O I：

10.1038/d41573-024-00020-8

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

A public-private partnership managed by the FNIH aims to address biological, manufacturing and regulatory challenges to the development of gene therapies for rare diseases. A public-private partnership managed by the FNIH aims to address biological, manufacturing and regulatory challenges to the development of gene therapies for rare diseases.

引用

页码：157 / 158

页数：2

共 50 条

[31] Gene therapy consortium
O'Driscoll, Cath
CHEMISTRY & INDUSTRY, 2021, 85 (11) : 8 - 8
[32] Improving access to gene therapy for rare diseases
Fox, Thomas A.
Booth, Claire
DISEASE MODELS & MECHANISMS, 2024, 17 (06)
[33] Ensuring a future for gene therapy for rare diseases
Alessandro Aiuti
Francesca Pasinelli
Luigi Naldini
Nature Medicine, 2022, 28 : 1985 - 1988
[34] Developing gene therapies for rare diseases: an interview with Geoff MacKay
MacKay, Geoff
REGENERATIVE MEDICINE, 2021, 16 (10) : 905 - 908
[35] Ensuring a future for gene therapy for rare diseases
Aiuti, Alessandro
Pasinelli, Francesca
Naldini, Luigi
NATURE MEDICINE, 2022, 28 (10) : 1985 - 1988
[36] Choroideremia: molecular mechanisms and development of AAV gene therapy
Patricio, Maria I.
Barnard, Alun R.
Xue, Kanmin
MacLaren, Robert E.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (07) : 807 - 820
[37] Potency Method Development Roadmap for AAV Gene Therapy
Beattie, Kimberley
MacArthur, Michael
Nattyaba, Martha
Fandunyan, Eugenia
Natu, Kalyani
MOLECULAR THERAPY, 2024, 32 (04) : 287 - 287
[38] Deamidation Analysis for Supporting AAV Gene Therapy Development
Zhou, Yu
Wang, Yueju
MOLECULAR THERAPY, 2023, 31 (04) : 61 - 61
[39] Development of AAV gene therapy for Morquio syndrome type A
Tomatsu, Shunji
Sawamoto, Kazuki
Kahn, Shaukat
Stapleton, Molly
Melethil, Subha
Danos, Olivier
MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S144 - S145
[40] Advances in AAV Vector Development for Gene Therapy in the Retina
Day, Timothy P.
Byrne, Leah C.
Schaffer, David V.
Flannery, John G.
RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY, 2014, 801 : 687 - 693

← 1 2 3 4 5 →